Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
(Thomson Reuters ONE) -
Novartis International AG /
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate
potential treatments in metastatic colorectal cancer
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Phase I/II study to evaluate Mekinist(®) (trametinib) in combination with
Opdivo(®) (nivolumab) and Opdivo + Yervoy(®) (ipilimumab)
* Collaboration expands upon existing clinical investigation of Opdivo
combination with Novartis investigational and marketed therapies
Basel, June 5, 2017 - Novartis today announced it has entered into a clinical
research collaboration in which Bristol-Myers Squibb will investigate the
safety, tolerability, and efficacy of Mekinist (trametinib) in combination with
Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential
treatment option for metastatic colorectal cancer in patients with
microsatellite stable tumors where the tumors are proficient in mismatch repair
(MSS mCRC pMMR).
Under the terms of the agreement, the study will be conducted by Bristol Myers-
Squibb and is expected to establish recommended dose regimens and the
preliminary anti-tumor activity of the combination therapies. Both Bristol
Myers-Squibb and Novartis will evaluate the results to determine optimal
approaches and potential clinical development of these combinations.
"Novartis has a longstanding heritage in exploring the combination of medicines
to broaden our knowledge of mutational driven cancers and develop innovative
treatments," said Vas Narasimhan, MD, Head, Global Drug Development and Chief
Medical Officer, Novartis. "Along with our ongoing internal immuno-oncology
efforts, the expansion of our collaboration with Bristol-Myers Squibb further
advances our collective goals to advance the science and to support patients in
need."
About Colorectal Cancer
Worldwide, colorectal cancer is the third most common type of cancer in men and
the second most common in women, with approximately 1.4 million new diagnoses in
2012. Of these, nearly 750,000 were diagnosed in men, and 614,000 in women[1].
Globally in 2012, approximately 694,000 deaths were attributed to colorectal
cancer[1]. In the U.S. alone, an estimated 135,430 patients will be diagnosed
with cancer of the colon or rectum in 2017, and approximately 50,000 are
estimated to die of their disease[2]. There is wide variation in 5-year survival
rates across disease stages, with 5-year survival rates for patients with
metastatic or stage IV colorectal cancer around 11%[3]. The incidence of
microsatellite stability (MSS) in colorectal tumors varies by stage, with 80% to
85% of exhibiting MSS[4].
About Mekinist and Important Safety Information
MEKINIST is a kinase inhibitor indicated, as a single agent or in combination
with dabrafenib, for the treatment of patients with unresectable or metastatic
melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
MEKINIST is not indicated for treatment of patients who have received prior
BRAF-inhibitor therapy. MEKINIST can cause serious side effects including new
primary malignancies (cutaneous and non-cutaneous), hemorrhage, inflammation of
the colon and perforation of the intestines, blood clots in the legs,
cardiomyopathy, eye toxicity, interstitial lung disease, serious fevers, serious
skin toxicity, hyperglycemia, and harm to a fetus. Some of these side effects
can be fatal in rare cases. The most common side effects when MEKINIST is used
as a single-agent are rash, diarrhea, and lymphedema.
About Opdivo
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is
designed to uniquely harness the body's own immune system to help restore anti-
tumor immune response. By harnessing the body's own immune system to fight
cancer, Opdivo has become an important treatment option across multiple cancers.
Opdivo's leading global development program is based on Bristol-Myers Squibb's
scientific expertise in the field of Immuno-Oncology and includes a broad range
of clinical trials across all phases, including Phase 3, in a variety of tumor
types. To date, the Opdivo clinical development program has enrolled more than
25,000 patients. The Opdivo trials have contributed to gaining a deeper
understanding of the potential role of biomarkers in patient care, particularly
regarding how patients may benefit from Opdivo across the continuum of PD-L1
expression.
In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive
regulatory approval anywhere in the world. Opdivo is currently approved in more
than 60 countries, including the United States, the European Union and Japan. In
October 2015, Bristol-Myers Squibb's Opdivo and Yervoy combination regimen was
the first Immuno-Oncology combination to receive regulatory approval for the
treatment of metastatic melanoma and is currently approved in more than 50
countries, including the United States and the European Union.
About Yervoy
Yervoy, which is a recombinant, human monoclonal antibody, blocks the cytotoxic
T- lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of
T-cell activation. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4
with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell
activation and proliferation. The mechanism of action of Yervoy effect in
patients with melanoma is indirect, possibly through T-cell mediated anti-tumor
immune responses. On March 25, 2011, the FDA approved Yervoy 3 mg/kg monotherapy
for patients with unresectable or metastatic melanoma. Yervoy is now approved in
more than 40 countries. There is a broad, ongoing development program in place
for Yervoy spanning multiple tumor types. This includes Phase 3 trials in
prostate and lung cancers.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "potential," "to evaluate," "will," "investigation,"
"investigational," "expected," "ongoing," "efforts," "goals," "may," or similar
terms, or by express or implied discussions regarding potential new indications
or labeling for Mekinist, potential new indications or labeling for other
products in the Novartis Oncology portfolio, or regarding potential future
revenues from Mekinist and such other products, and potential future revenues
arising from the clinical research collaboration with Bristol-Myers Squibb. You
should not place undue reliance on these statements. Such forward-looking
statements are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Mekinist or other products of Novartis and
Bristol-Myers Squibb subject to the clinical research collaboration will be
submitted or approved for any additional indications or labeling in any market,
or at any particular time. Neither can there be any guarantee that the clinical
research collaboration with Bristol-Myers Squibb will achieve any or all of its
intended goals and objectives, or be successful. Nor can there be any guarantee
that any other product in the Novartis Oncology portfolio will be submitted or
approved for any additional indications or labeling in any market, or at any
particular time. Neither can there be any guarantee that Mekinist, any of the
other products subject to the clinical research collaboration with Bristol-Myers
Squibb, or any other product in the Novartis Oncology portfolio will be
commercially successful in the future. In particular, management's expectations
regarding such products, and the clinical research collaboration with Bristol-
Myers Squibb, could be affected by, among other things, the uncertainties
inherent in research and development, including clinical trial results and
additional analysis of existing clinical data; regulatory actions or delays or
government regulation generally; the company's ability to obtain or maintain
proprietary intellectual property protection; general economic and industry
conditions; global trends toward health care cost containment, including ongoing
pricing and reimbursement pressures; safety, quality or manufacturing issues,
and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
Opdivo(®) and Yervoy(®) are registered trademarks of Bristol Myers-Squibb.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2016, the Group achieved
net sales of USD 48.5 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
118,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis and (at)Novartis Cancer at
http://twitter.com/novartiscancer.
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: A
Cancer Journal for Clinicians, 65: 87-108.
[2] Colorectal Cancer Facts & Figures. American Cancer Society. Available at:
https://www.cancer.org/research/cancer-facts-statistics/colorectal-cancer-facts-
figures.html. Accessed June 4, 2017.
[3] Colorectal Cancer: Early Detection, Diagnosis, and Staging. American Cancer
Society. Available at: https://www.cancer.org/cancer/colon-rectal-
cancer/detection-diagnosis-staging/survival-rates.html. Updated March 2, 2017.
Accessed June 4, 2017.
[4] Chapelle A, Hampel H. Clinical Relevance of Microsatellite Instability in
Colorectal Cancer. Journal of Clinical Oncology. 2010; 28 (20): 3380-3387.
Available at: http://dx.doi.org/10.1200/JCO.2009.27.0652.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Kristen Klasey
Novartis Global Media Relations Novartis Oncology Communications
+41 61 324 7999 (direct) +862 778 4763 (direct)
+41 79 593 4202 (mobile) +862 754 1732 (mobile)
eric.althoff(at)novartis.com kristen.klasey(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media release (PDF):
http://hugin.info/134323/R/2110529/802147.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.06.2017 - 22:05 Uhr
Sprache: Deutsch
News-ID 546355
Anzahl Zeichen: 13405
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
